--A state court in Philadelphia, PA, on Tuesday handed down a verdict ordering Bayer AG (BAYN.XE) and Johnson & Johnson (JNJ), the makers of the blood thinner Xarelto, to pay $27.8 million after their failure to warn of the drug's internal bleeding risks, says Reuters.

--The verdict awarded $1.8 million in compensatory damages and $26 million in punitive damages, says Reuters, citing the plaintiff's lawyer. Both Bayer and Johnson & Johnson said they would appeal the verdict.

--Xarelto is Bayer's best-selling drug, according to Reuters, contributing 2.9 billion euros ($3.41 billion) in revenue to the company in 2016.

--This is Bayer and Johnson & Johnson's first Xarelto-related trial loss, having been cleared of liability in three previous federal trials, notes Reuters. Tuesday's case was the first of some 1,400 Xarelto cases pending in the Philadelphia court and there are more than 18,500 Xarelto cases pending in federal court.

Full story: http://reut.rs/2jkFavX

Write to Barcelona editors at barcelonaeditors@dowjones.com

(END) Dow Jones Newswires

December 06, 2017 06:31 ET (11:31 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.